Empirical treatment by antifungal drugs in febrile neutropenia

Journal de Mycologie Medicale

Volumn 12, Issue 3, 2002, Pages 115-119

  Thiebaut, Anne ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Empiric treatment; Invasive fungal infections

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CYTARABINE; FLUCONAZOLE; ITRACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; EARLY DIAGNOSIS; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; REVIEW; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036745681     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Beck-Sague CM, Jarvis WR, The National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167:1247-51.
2. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli A, Schwarer AP. Intravenous and oral itraconazole versus intravenous amphotericin B deosycholate as empirical antifungal-therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med 2001;135:412-22.
3. Caillot D., Casasnovas O, Bernard A, Couallier JF, Durand C, Cuisenier B et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47.
4. Denning DW, Marinus A, Cohen J, Spencer D, Herbrecht R, Pagano L et al. An EORTC multicentre prospective survey of invasive aspergilllosis in haematological patients: diagnosis and therapeutic out. come. EORTC lnvasive Fungal Infections Cooperative Group. J Infect 1998;37:173-80.
5. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-years analysis. Clin Infect Dis 1999;29:239-44.
6. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
7. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001;7:8-24.
8. Malik IA, Moid I, Aziz Z, Khan S, Suleman M A randomised comparaison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and reutropenia. Am J Med 1998;105:478-83.
9. Marr KA. Ampirical aniifungal therapy-new options, new tradeoffs. N Engl J Med 2002;346:278-80.
10. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990;17:10-3.
11. Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996;22:S112-8.
12. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11. Powers JH. Counterpoint: alternative trial designs for antifungal drugs-time to talk. Clin Infect Dis 2001;33:107-9.
13. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11. Powers JH. Counterpoint: alternative trial designs for antifungal drugs-time to talk. Clin Infect Dis 2001;33:107-9.
14. Prentice HG, Hann IM, Hrebrecht R, Aoun M, Kvaloy S, Catovsky D et al. A randomized comparaison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-18.
15. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000;110:273-284.
16. Rex JH, Walsh TJ, Nettleman M, Anaissie EJ, Bennett JE, Bow EJ et al. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 2001;33:95-106.
17. Viscoli C, Castagnola E, Van Lint MT. Morono C, Garaventa A, Rossi MR et al. Fluconazole versus amphotericinB as empirical antifungal therapy of unexplained fever in ganulocytopenic cancer patients: a pragmatic, multicenter, prospective and randomised clinical trial. Eur J Cancer 1996;32A:814-20.
18. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D et al. Liposomal amphotericinB for empirical treatment in patients with persistent fever and neutropenia. N Engl J Med 1999;340: 761-71.
19. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F. Raffalli J. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutopenia and persistent fever. N Engl J Med 2002;346:225-34.
20. Walsh TJ, Yeidandi V, McEvoy M, Gonzales C, Chanock SJ, Freifeld A et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998;42:2391-8.
21. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
22. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-63.
23. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrils neutropenis patients with cancer. Am J Med 2000;108:282-9.